​

Evotec SE (EVO) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

EVO Stock Forecast

Evotec SE (EVO) stock forecast, based on 7 Wall Street analysts, predicts a 12-month average price target of $8.00, with a high of $8.00 and a low of $8.00. This represents a 144.65% increase from the last price of $3.27.

$3 $4 $5 $6 $7 $8 $9 $10 $11 $12 High: $8 Avg: $8 Low: $8 Last Closed Price: $3.27

EVO Stock Rating

Evotec SE stock's rating consensus is Buy, based on 7 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 4 Buy (57.14%), 3 Hold (42.86%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 7 0 3 4 Strong Sell Sell Hold Buy Strong Buy

EVO Price Target Upside V Benchmarks

TypeNameUpside
StockEvotec SE144.65%
SectorHealthcare Stocks 33.91%
IndustrySpecialty & Generic Drug Manufacturers Stocks46.81%

Price Target Trends

1M3M12M
# Anlaysts--2
Avg Price Target--$9.50
Last Closing Price$3.27$3.27$3.27
Upside/Downside--190.52%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 2531--15
Mar, 25211-15
Feb, 25212-16
Jan, 25212-16
Dec, 24212-16
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Aug 15, 2024Douglas TsaoH.C. Wainwright$8.00$3.22148.45%144.65%
Apr 25, 2024Douglas TsaoH.C. Wainwright$11.00$5.23110.33%236.39%
Dec 09, 2022H.C. Wainwright$12.00$8.3843.20%266.97%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 07, 2024JefferiesHolddowngrade
Aug 15, 2024H.C. WainwrightBuyBuyhold
Aug 08, 2024Deutsche BankHoldSelldowngrade
Aug 07, 2024Oddo BHFNeutraldowngrade
Jul 29, 2024Morgan StanleyOverweightEqual-Weightdowngrade
Jul 11, 2024Deutsche BankBuyHolddowngrade
Jun 28, 2024Cowen & Co.BuyBuyhold
Apr 25, 2024H.C. WainwrightBuyBuyhold
Apr 12, 2024Deutsche BankHoldBuyupgrade
Aug 31, 2023CitigroupBuyBuyhold

Financial Forecast

EPS Forecast

Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$0.04$1.30$-0.99$-0.47-----
Avg Forecast$0.08$0.72$-0.35$-0.16$-0.40$-0.11$0.04$0.25$0.36
High Forecast$0.08$0.75$-0.34$-0.08$-0.27$0.01$0.04$0.26$0.38
Low Forecast$0.08$0.68$-0.38$-0.33$-0.49$-0.26$0.04$0.24$0.35
Surprise %-50.00%80.56%182.86%193.75%-----

Revenue Forecast

$500M $700M $900M $1B $1B $2B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$500.92M$618.03M$751.45M$781.43M-----
Avg Forecast$576.86M$643.87M$773.56M$846.56M$860.79M$971.37M$1.11B$1.25B$1.44B
High Forecast$595.77M$664.97M$813.02M$872.84M$877.16M$980.98M$1.14B$1.29B$1.48B
Low Forecast$552.44M$616.61M$751.14M$820.26M$844.42M$952.14M$1.08B$1.21B$1.39B
Surprise %-13.16%-4.01%-2.86%-7.69%-----

Net Income Forecast

$-200M $-110M $-20M $70M $160M $250M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$6.28M$215.51M$-175.66M$-83.91M-----
Avg Forecast$14.11M$127.30M$-62.56M$-28.88M$-70.38M$-19.95M$6.91M$44.32M$64.23M
High Forecast$14.72M$132.72M$-60.20M$-13.68M$-48.07M$2.22M$7.18M$46.04M$66.73M
Low Forecast$13.34M$120.29M$-66.71M$-57.76M$-87.55M$-46.56M$6.65M$42.63M$61.78M
Surprise %-55.52%69.30%180.78%190.54%-----

EVO Forecast FAQ

Is Evotec SE stock a buy?

Evotec SE stock has a consensus rating of Buy, based on 7 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 4 Buy, 3 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Evotec SE is a favorable investment for most analysts.

What is Evotec SE's price target?

Evotec SE's price target, set by 7 Wall Street analysts, averages $8 over the next 12 months. The price target range spans from $8 at the low end to $8 at the high end, suggesting a potential 144.65% change from the previous closing price of $3.27.

How does Evotec SE stock forecast compare to its benchmarks?

Evotec SE's stock forecast shows a 144.65% upside, outperforming the average forecast for the healthcare stocks sector (33.91%) and outperforming the specialty & generic drug manufacturers stocks industry (46.81%).

What is the breakdown of analyst ratings for Evotec SE over the past three months?

  • April 2025: 60.00% Strong Buy, 20.00% Buy, 0% Hold, 0% Sell, 20.00% Strong Sell.
  • March 2025: 40.00% Strong Buy, 20.00% Buy, 20.00% Hold, 0% Sell, 20.00% Strong Sell.
  • February 2025: 33.33% Strong Buy, 16.67% Buy, 33.33% Hold, 0% Sell, 16.67% Strong Sell.

What is Evotec SE’s EPS forecast?

Evotec SE's average annual EPS forecast for its fiscal year ending in December 2024 is $-0.4, marking a -14.89% decrease from the reported $-0.47 in 2023. Estimates for the following years are $-0.11 in 2025, $0.04 in 2026, $0.25 in 2027, and $0.36 in 2028.

What is Evotec SE’s revenue forecast?

Evotec SE's average annual revenue forecast for its fiscal year ending in December 2024 is $860.79M, reflecting a 10.16% increase from the reported $781.43M in 2023. The forecast for 2025 is $971.37M, followed by $1.11B for 2026, $1.25B for 2027, and $1.44B for 2028.

What is Evotec SE’s net income forecast?

Evotec SE's net income forecast for the fiscal year ending in December 2024 stands at $-70.381M, representing a -16.13% decrease from the reported $-83.913M in 2023. Projections indicate $-19.954M in 2025, $6.91M in 2026, $44.32M in 2027, and $64.23M in 2028.